论文部分内容阅读
Objective Investigation of efficacy and safety in different retina diseases compared newly launched anti-VEGF aflibercept (VEGF Trap-Eye; Regeneron, Tarrytown, NY,and BayerHealthCare, Berlin, Germany) with currently used anti-VEGF Ranibizumab(Lucentis; Genentech,South San Francisco, California, USA).